The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 3 ( July-September, 2022 ) > List of Articles

SHORT COMMUNICATION

Pragmatic Real-world Approach to Treat Diffuse Parenchymal Lung Disease in Logistically Constraint Situations: A Proposition

Parthasarathi Bhattacharyya

Keywords : Bronchoalveolar lavage, Collagen vascular disease–interstitial lung disease, Diffuse parenchymal lung disease, Hypersensitivity pneumonitis, Idiopathic progressive fibrosis, Multidisciplinary discussion, Non-specific interstitial pneumonia, Progressive fibrotic phenotype of interstitial lung disease, Real world, Sarcoidosis

Citation Information : Bhattacharyya P. Pragmatic Real-world Approach to Treat Diffuse Parenchymal Lung Disease in Logistically Constraint Situations: A Proposition. Indian J Chest Dis Allied Sci 2022; 64 (3):230-233.

DOI: 10.5005/jp-journals-11007-0022

License: CC BY-NC 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Understanding the etiology and the tempo of progression with inexorable and self-perpetuating fibrosis [identification of progressive-fibrotic (PF) phenotype of interstitial lung disease (ILD) (PF-ILD)] can help to decide the treatment of diffuse parenchymal lung disease (DPLD) in the real-world practice. An evidence-supported pragmatic approach has been forwarded for such circumstances.


HTML PDF Share
  1. Wilson MS, Wynn TA. Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal Immunol 2009;2(2):103–121. DOI: 10.1038/mi.2008.85.
  2. Ryu JH, Olson EJ, Midthun DE, et al. Diagnostic approach to the patient with diffuse lung disease. Mayo Clin Proc 2002;77(11):1221–1227. DOI: 10.4065/77.11.1221.
  3. Collard HR, King TE Jr. Demystifying idiopathic interstitial pneumonia. Arch Intern Med 2003;163(1):17–29. DOI: 10.1001/archinte.163.1.17.
  4. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. American journal of respiratory and critical care medicine. 2005;172(3):268–279. DOI: 10.1164/rccm.200503-483OE.
  5. Bryson T, Sundaram B, Khanna D, et al. Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: Similarity and difference. Semin Ultrasound CT MR 2014; 35(1):29–38. DOI: 10.1053/j.sult.2013.10.010.
  6. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Cre Med 2013;188(6):733–748. DOI: 10.1164/rccm.201308-1483ST.
  7. Bhattacharyya P. Lessons from the interstitial lung disease – India registry: A proposed practical scheme of classification of diffuse parenchymal lung diseases in the Indian subcontinent. Lung India 2018;35(5):428–430. DOI: 10.4103/lungindia.lungindia_393_17.
  8. Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Cre Med 2017;195(6):801–813. DOI: 10.1164/rccm.201607-1484OC.
  9. Raghu G, Remy–Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Cre Med 2018;198(5):e44–e68. DOI: 10.1164/rccm.201807-1255ST.
  10. Raghu G, Remy–Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Cre Med 2020;202(3):e36–e69. DOI: 10.1164/rccm.202005-2032ST.
  11. ER FP, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST Guideline and Expert Panel Report – Executive Summary. Chest 2021;160(2):595–615. DOI: 10.1016/j.chest. 2021.03.067.
  12. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Cre Med 2012;185(9):1004–1014. DOI: 10.1164/rccm.201202-0320ST.
  13. Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27(150):180076. DOI: 10.1183/16000617.0076-2018.
  14. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Cre Med 2011;183(6):788–824. DOI: 10.1164/rccm.2009-040GL.
  15. Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: Knowns and unknowns. Eur Respir Review 2019;28(151):180100. DOI: 10.1183/16000617.0100-2018.
  16. Horst C, Gholipour B, Nair A, et al. Differential diagnoses of fibrosing lung diseases. BJR Open 2019;1(1):20190009. DOI: 10.1259/bjro.20190009.
  17. Wells AU, Brown KK, Flaherty KR, et al. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51(5):1800692. DOI: 10.1183/13993003.00692-2018.
  18. Wollin L, Distler JH, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019;54(3):1900161. DOI: 10.1183/13993003.00161-2019.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.